D-FI Trademark

Trademark Overview

On Tuesday, November 30, 2021, a trademark application was filed for D-FI with the United States Patent and Trademark Office. The USPTO has given the D-FI trademark a serial number of 97149164. The federal status of this trademark filing is SU - NON-FINAL ACTION - MAILED as of Wednesday, November 13, 2024. This trademark is owned by Castle Creek Biosciences, LLC. The D-FI trademark is filed in the Pharmaceutical Products category with the following description:

Gene therapy products, namely, genetically modified cells for medical use for the treatment of dystrophic epidermolysis bullosa; pharmaceutical preparations and injectable biological preparations containing genetically modified materials for treatment of dystrophic epidermolysis bullosa; Pharmaceutical preparations and therapeutic preparations for treatment of skin diseases, connective tissue diseases, arthritis and autoimmune diseases
d-fi

General Information

Serial Number97149164
Word MarkD-FI
Filing DateTuesday, November 30, 2021
Status807 - SU - NON-FINAL ACTION - MAILED
Status DateWednesday, November 13, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 16, 2023

Trademark Statements

Goods and ServicesGene therapy products, namely, genetically modified cells for medical use for the treatment of dystrophic epidermolysis bullosa; pharmaceutical preparations and injectable biological preparations containing genetically modified materials for treatment of dystrophic epidermolysis bullosa; Pharmaceutical preparations and therapeutic preparations for treatment of skin diseases, connective tissue diseases, arthritis and autoimmune diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, April 6, 2023
Primary Code005
First Use Anywhere DateSaturday, January 22, 2022
First Use In Commerce DateSaturday, January 22, 2022

Trademark Owner History

Party NameCastle Creek Biosciences, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressExton, PA 19341
Party NameCastle Creek Biosciences, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressExton, PA 19341

Trademark Events

Event DateEvent Description
Wednesday, August 31, 2022TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Friday, December 3, 2021NEW APPLICATION ENTERED
Saturday, December 4, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, August 31, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, August 31, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, August 31, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, September 8, 2022ASSIGNED TO EXAMINER
Tuesday, September 13, 2022NON-FINAL ACTION WRITTEN
Tuesday, September 13, 2022NON-FINAL ACTION E-MAILED
Tuesday, September 13, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, March 13, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, March 13, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, March 15, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, March 20, 2023EXAMINERS AMENDMENT -WRITTEN
Monday, March 20, 2023EXAMINERS AMENDMENT E-MAILED
Monday, March 20, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, March 20, 2023EXAMINER'S AMENDMENT ENTERED
Thursday, April 6, 2023EXAMINERS AMENDMENT -WRITTEN
Thursday, April 6, 2023EXAMINERS AMENDMENT E-MAILED
Thursday, April 6, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, April 6, 2023EXAMINER'S AMENDMENT ENTERED
Tuesday, April 11, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 26, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 16, 2023PUBLISHED FOR OPPOSITION
Tuesday, May 16, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 11, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, January 11, 2024USE AMENDMENT FILED
Thursday, January 11, 2024SOU TEAS EXTENSION RECEIVED
Thursday, January 11, 2024SOU EXTENSION 1 FILED
Thursday, January 11, 2024TEAS STATEMENT OF USE RECEIVED
Monday, January 29, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, January 29, 2024SOU EXTENSION 1 GRANTED
Tuesday, January 30, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 29, 2024STATEMENT OF USE PROCESSING COMPLETE
Wednesday, November 13, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, November 13, 2024SU - NON-FINAL ACTION - WRITTEN
Wednesday, November 13, 2024NON-FINAL ACTION E-MAILED
Thursday, February 13, 2025APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Thursday, February 13, 2025APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED

Related Keywords

preparations diseases treatment dystrophic bullosa epidermolysis pharmaceutical genetically modified therapy